N. Harry Hendrikse
Amsterdam University Medical Centers, Amsterdam UMC Location VUmc, Cancer Center Amsterdam
Papers
6
Total Citations
133
H-Index
5
About
N. Harry Hendrikse is a leading researcher in the field of urologic oncology, with a primary focus on the application of prostate-specific membrane antigen (PSMA) PET/CT imaging for the diagnosis and management of prostate cancer. His major contributions center on validating the clinical utility of 18F-DCFPyL PSMA-PET/CT, demonstrating its superior accuracy in detecting primary and recurrent prostate cancer compared to conventional imaging. Notably, his work on the DeTeCT trial (47 citations) established the feasibility of PSMA-targeted biopsies by correlating PET findings with final histopathology. Hendrikse has also pioneered research linking standardized uptake values (SUVmax) on PSMA PET/CT to oncological outcomes (27 citations), providing a non-invasive prognostic tool. His studies have significantly impacted clinical decision-making, showing that PSMA PET/CT can guide the omission of unnecessary pelvic lymph node dissections and alter treatment management in up to 40% of patients with biochemical recurrence. With over 130 cumulative citations, Hendrikse’s work is instrumental in advancing precision medicine for prostate cancer, helping to reduce overtreatment while improving the detection of metastatic disease.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6